TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02240485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Couple Treatment for Pathological Gambling (ICT-PG)
Description: The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Therapy for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors incompatible with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual individual/group treatment
Description: The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
Study: NCT03337230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Fitbit Activity Monitor and IPAQ to give level of physical activity. Participants will be provided with education about physical activity recommendations and will be encouraged to set goals for improvement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: National Cancer Institute's ASA24 web-based dietary assessment tool to determine intake. Participants will be provided with education about healthy diets and will be encouraged to set goals for making enduring changes to dietary intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Social support will be determined via self report scale measure and objective collection of social media communications. Each participant will be contacted through social media regularly with dietary and physical activity information and asked to support other participants via encouragement and sharing of information.
Study: NCT04427527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level intervention to increase CRC screening
Description: Intervention for the community, providers, patients, clinics and systems
Study: NCT04915846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ApoTamox 10mg
Description: All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week). Participants and study staff will be blinded as to whether the participants are starting with the placebo or the drug. Depending on randomization, drug or placebo will be dispensed at the end of the t=0 study visit (Phase 1). Dosing will commence the day after the t=0 study visit. At the end of Phase 1, participants will enter a 'washout' period, when they will cease treatment. After approximately 3 months of washout, participants will cross-over to the other treatment regimen and receive the other interventional product (IP) for the final 6 months of their study participation (Phase 2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator
Study: NCT03344757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cultural CBSM
Description: The Culturally Adapted Cognitive Behavioral Stress Management (C-CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own. The delivery of C-CBSM places a greater emphasis on salient sociocultural determinants of symptom burden and Health Related Quality of Life (HRQoL) in Hispanics (e.g., fatalistic attitudes, family interdependence, perceived discrimination, machismo).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard CBSM
Description: The standard Cognitive Behavioral Stress Management (CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own.
Study: NCT00028665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide IV over 3-6 hours on day 16.
Study: NCT03651635

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling for MR-proADM & CT-proET-1
Description: Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM \& CT-proET-1
Study: NCT02981108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296
Description: HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.
Study: NCT04361734

Intervention type: OTHER
Intervention: Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)
Description: * Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.~* Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.~* Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body.

Intervention type: OTHER
Intervention: Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)
Description: * Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.~* Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.~* Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body.

Intervention type: OTHER
Intervention: Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)
Description: * Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.~* Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.~* Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body.
Study: NCT00788463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Beclomethasone aerosol
Description: Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Beclomethasone spray
Description: Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
Study: NCT03963765

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group I (Standard DL-PDT)
Description: Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group II (DL-PDT with microneedles)
Description: Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microneedles - motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) as a techniques of transepidermal drug delivery (TED)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group III (DL-PDT with CO2 laser)
Description: Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density \<1% (Pixel Alma Lasers ®) was applied, single-pass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group IV (DL-PDT with microdermabrasion)
Description: Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microdermabrasion - aluminum oxide crystal (Pan Eletronic®) as a techniques of transepidermal drug delivery (TED)
Study: NCT00697502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.~Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.~Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period.
Study: NCT04076085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Stretching exercise for warmup, All arm exercise with and without weights as tolerated by the patients. Similarly lower limb exercise in different positions like lying standing as tolerated by the patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Stretching exercise for warmup, All arm exercise with and without weights as tolerated by the patients. Similarly lower limb exercise in different positions like lying standing as tolerated by the patients
Study: NCT02367573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D laparoscopic TAPP inguinal hernia repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic TAPP inguinal hernia repair
Study: NCT00723996

Intervention type: BEHAVIORAL
Intervention: Behavioral Study in Women
Description: A Randomized study to assess the knowledge of womens health related issues

Intervention type: BEHAVIORAL
Intervention: Behavioral Study in Women
Description: A Randomized study to assess the knowledge of womens health related issues
Study: NCT03168477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Dry needling to the supraspinatus (proximal/distal teno-osseus junction and musculotendinous junction under acromion process), deltoid muscle, upper trapezius muscle and levator scapulae muscle on the painful side. Clinicians may also needle the terres major, infraspinatous, rhomboids and thoracic paraspinals, as needed. Up to 12 treatment sessions over 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal manipulation
Description: HVLA thrust manipulation to cervical, thoracic and/or upper rib articulation (R1-R3).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobilization
Description: Impairment-based mobilization targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Impairment-based exercise targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modalities
Description: Interferential electrotherapy targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
Study: NCT04361071

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent
Description: stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plaque excision system
Description: plaque excision system
Study: NCT03664297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459
Description: SHR1459 will be administered continually till disease progression or unacceptable toxicity.
Study: NCT01793428

Intervention type: OTHER
Intervention: Capillary lactate level
Description: Use of capillary sample to determine lactate level upon arrival at vital emergency unit and at 2 hours
Study: NCT02278406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep brain stimulator
Description: We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
Study: NCT00028665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: cyclophosphamide IV over 3-6 hours on day 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: Patients then undergo peripheral blood stem cell (PBSC) collection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow ablation with stem cell support
Description: Patients then undergo peripheral blood stem cell (PBSC) collection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.
Study: NCT02035709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.
Study: NCT02885337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Modal Frailty Intervention
Description: Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with the patient at a physiotherapist clinic. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption.
Study: NCT03056274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin Hydrochloride (HCl) Tablets, is an oral antihyperglycemic drug used in the management of type 2 diabetes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid (UDCA) is used to treat gallstones and primary biliary cirrhosis. UDCA is also used to treat obstetric cholestasis (OC), a liver condition that occurs specifically in pregnancy.
Study: NCT02551497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV1014802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV1014802
Study: NCT00331890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: 1g/12h iv during 3 days and then orally until complete 6 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As active drug
Study: NCT02553369

Intervention type: OTHER
Intervention: Biological sample collection
Description: A blood sample is collected during a follow up visit for HIV infection.
Study: NCT04713059

Intervention type: GENETIC
Intervention: FGFR2
Description: Mutation of FGFR2

Intervention type: GENETIC
Intervention: FGFR2
Description: Mutation of FGFR2
Study: NCT01261884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise support
Description: Group B (exercise support) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, and a pedometer. This group will be asked to wear the pedometer for 7 consecutive days between Visits 1 and 2, and record daily activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Group C (exercise intervention) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, a pedometer, a resistance band, and a handout on specific exercises (type and frequency) to be performed. The study coordinator will demonstrate each exercise and then observe the participant perform each exercise to assure full understanding. In addition to wearing the pedometer for 7 days and completing the activity log, this group will also record compliance with the exercise regimen.
Study: NCT03148574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: intrauterine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: intravenous
Study: NCT00379548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 groups of population responding to 2 types of diets
Description: Intervention groups include: Asian intervention and Caucasian intervention- both these groups switch from an Asian diet to a Western diet halfway through the study.
Study: NCT00136201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Study: NCT04620174

Intervention type: OTHER
Group type: OTHER
Intervention: Custom-made zirconia crowns
Description: Ten decayed primary molars will be restored with custom-made zirconia crowns.

Intervention type: OTHER
Group type: OTHER
Intervention: Prefabricated zirconia crowns
Description: Ten decayed primary molars will be restored with prefabricated zirconia crowns.
Study: NCT02493244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cliradex
Description: Cliradex is simply water and 4-Terpineol, a natural organic compound found Melaleuca alternifolia. The other ingredients in Cliradex are in less than 1% of the formulation and are Glycerin, Polysorbate 20, Polysorbate 80, Carbomer, Triethanolamine.
Study: NCT02184130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation and motion stimuli
Study: NCT01861366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A one year multifaceted implementation strategy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A three hour lecture about the guidelines
Study: NCT04038060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp Group
Description: Participants will receive peer adherence support through WhatsApp groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp Group
Description: Participants will receive peer adherence support through WhatsApp groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp Group
Description: Participants will receive peer adherence support through WhatsApp groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-way SMS
Description: Participants will receive healthcare worker adherence support through 2-way SMS
Study: NCT02981108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296
Description: HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296
Description: HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.